Justin Chakma Net Worth, Biography, and Insider Trading
InsiderTrades.com logo
Justin Chakma net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Justin Chakma Biography and Net Worth

Chief Business Officer of ARS Pharmaceuticals

Justin Chakma has served as our Chief Business Officer since June 2019. From 2018 to May 2019, Mr. Chakma served as VP, Head of Business Development and Strategy at Vedanta Biosciences, a biotechnology company developing medicines to modulate immune responses. Before that, from 2015 to 2018, he was a Senior Director of Business Development at Celgene Corporation (formerly Nasdaq: CELG) (acquired by Bristol-Myers Squibb Company). Prior to joining Celgene, Mr. Chakma held various roles in biotech and pharmaceutical business development, financing and investments at Receptos, Inc. (formerly Nasdaq: RCPT) (acquired by Celgene), Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX) (acquired by Teva Pharmaceutical Industries Ltd.), and Thomas, McNerney & Partners, a venture capital firm. Mr. Chakma holds an M.B.A. from the Wharton School of the University of Pennsylvania, and bachelor’s degrees in neuroscience and economics from the University of Toronto.

What is Justin Chakma's net worth?

The estimated net worth of Justin Chakma is at least $1.70 million as of December 13th, 2024. Mr. Chakma owns 136,380 shares of ARS Pharmaceuticals stock worth more than $1,703,386 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Chakma may own. Learn More about Justin Chakma's net worth.

How old is Justin Chakma?

Mr. Chakma is currently 34 years old. There are 6 older executives and no younger executives at ARS Pharmaceuticals. The oldest executive at ARS Pharmaceuticals is Mr. Harris Kaplan M.B.A., Executive Vice President of Commercial Strategy, who is 72 years old. Learn More on Justin Chakma's age.

How do I contact Justin Chakma?

The corporate mailing address for Mr. Chakma and other ARS Pharmaceuticals executives is 500 Fairview Ave N Suite 600, Seattle WA, 98109. ARS Pharmaceuticals can also be reached via phone at 206-456-2900 and via email at ir@silverbacktx.com. Learn More on Justin Chakma's contact information.

Has Justin Chakma been buying or selling shares of ARS Pharmaceuticals?

Justin Chakma has not been actively trading shares of ARS Pharmaceuticals within the last three months. Most recently, Justin Chakma sold 27,272 shares of the business's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $12.06, for a transaction totalling $328,900.32. Following the completion of the sale, the insider now directly owns 136,380 shares of the company's stock, valued at $1,644,742.80. Learn More on Justin Chakma's trading history.

Who are ARS Pharmaceuticals' active insiders?

ARS Pharmaceuticals' insider roster includes Justin Chakma (Chief Business Officer), Brian Dorsey (Chief Operating Officer), Alexander Fitzpatrick (Chief Legal Officer), Eric Karas (Chief Commercial Officer), Richard Lowenthal (President and Chief Executive Officer), Kathleen Scott (Chief Financial Officer), Laura Shawver (Director), Sarina Tanimoto (Chief Medical Officer), and Peter Thompson (Director). Learn More on ARS Pharmaceuticals' active insiders.

Are insiders buying or selling shares of ARS Pharmaceuticals?

In the last twelve months, insiders at the sold shares 37 times. They sold a total of 2,961,053 shares worth more than $39,496,274.18. The most recent insider tranaction occured on March, 20th when insider Eric Karas sold 10,000 shares worth more than $140,000.00. Insiders at ARS Pharmaceuticals own 40.1% of the company. Learn More about insider trades at ARS Pharmaceuticals.

Information on this page was last updated on 3/20/2025.

Justin Chakma Insider Trading History at ARS Pharmaceuticals

See Full Table

Justin Chakma Buying and Selling Activity at ARS Pharmaceuticals

This chart shows Justin Chakma's buying and selling at ARS Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

ARS Pharmaceuticals Company Overview

ARS Pharmaceuticals logo
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $12.49
Low: $12.21
High: $12.78

50 Day Range

MA: $12.15
Low: $10.18
High: $14.88

2 Week Range

Now: $12.49
Low: $7.55
High: $18.51

Volume

1,191,077 shs

Average Volume

1,074,219 shs

Market Capitalization

$1.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03